Ravi Vij, MD, MBA, discusses how measurable residual disease (MRD) testing is shaping treatment decisions in hematology and its potential to reduce costs and toxicity. Measurable residual disease (MRD ...
Experts discuss how MRD testing in myeloma increasingly guides frontline care, yet unanswered questions still limit using MRD as the sole benchmark. This episode, titled 'MRD Negativity as a Benchmark ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation Trials, LLC (AFT) and the Austrian Breast and ...
New prospective sub-study analysis data presented by Abbott at the 2026 American Society of Clinical Oncology (ASCO) meeting has highlighted the value of minimal residual disease (MRD) testing in ...
Marks third NCCN guideline recommendation on ctDNA-MRD testing, following positive guideline changes in merkel cell carcinoma and diffuse large b-cell lymphoma AUSTIN, Texas--(BUSINESS WIRE)--Natera, ...
CURE spoke with a provider and a survivor about the potential power of minimal residual disease testing. Minimal residual disease, or MRD, testing may have the potential to offer peace of mind to ...
Quest Diagnostics debuts a new blood test for myeloma MRD, offering NGS-level sensitivity and a less invasive alternative to bone marrow biopsies. Quest Diagnostics has announced the launch of a novel ...
New data from Natera has demonstrated its Signatera molecular residual disease (MRD) test’s role in determining which resected colorectal liver metastases (CRLM) patients may benefit from adjuvant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results